The process in Ireland for health technology assessment (HTA) uses a rapid review to triage products where uncertainty is greatest from those where outcomes are more certain.

Results from this study indicated that a greater proportion of orphan products than non-orphan products required a full HTA.

National authorities need to ensure that their decision-making framework can adequately capture the uncertainty posed by these orphan drugs (relative to non-orphan drugs).